Compare Quest Diagnostics Inc (DGX) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Firy Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Firy Inc. trades at $12.07 (market cap $199.80M). The key difference: Quest Diagnostics Inc is far larger — about 127.5× Firy Inc.'s market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Firy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Firy Inc. for 13 Days on average.
| DGX | FIRY | |
|---|---|---|
Market Cap | $25.48B | $199.80M |
Volume | 941,866 | 92,993 |
Sector | Health | Technology |
52-Week High | $247.45 | $13.10 |
52-Week Low | $173.49 | $2.28 |
Typical Hold Time | 56 Days | 13 Days |
Enterprise Value | $31.23B | $168.40M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
FIRY trades at $12.02, up 1.43% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but missed EPS expectations with a net loss. Recent developments include a $719M legal victory and board appointment of Marc Lasry, though cash flow remains negative with -$86.41M in 2025.
Outlook is mixed: the legal win and restructuring offer potential upside, but persistent losses and cash burn pose significant risks. Analyst consensus is cautious with 60% hold ratings. The stock's valuation at P/S 1.6x appears reasonable, but profitability challenges and negative margins require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
